Latest & greatest articles for isosorbide mononitrate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on isosorbide mononitrate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on isosorbide mononitrate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for isosorbide mononitrate

1. Isosorbide mononitrate

Isosorbide mononitrate Top results for isosorbide mononitrate - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might (...) look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for isosorbide mononitrate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical

2018 Trip Latest and Greatest

2. [Isosorbide-5-mononitrate in the prevention of digestive hemorrhage in cirrhosis: randomized study]. (Abstract)

[Isosorbide-5-mononitrate in the prevention of digestive hemorrhage in cirrhosis: randomized study]. Isosorbide 5-mononitrate (5MI) is a preferential venous dilator that has been shown to decrease portal pressure in acute and long-term haemodynamic studies, and this is not associated with adverse effects on hepatic perfusion. The aim of this trial was to investigate the efficacy and safety of 5MI in the prevention of upper gastrointestinal bleeding in cirrhotic patients. Forty two cirrhotic

1993 Acta gastroenterologica Latinoamericana Controlled trial quality: uncertain

3. Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients. Full Text available with Trip Pro

Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients. Both drug therapy and banding ligation are widely used in the prevention of first variceal bleeding. This study compared the efficacy and safety of band ligation vs. combination of beta-blocker and nitrate for the prevention of first bleeding in patients with cirrhosis and high-risk esophageal varices.A total of 61 patients with cirrhosis (...) with moderate or severe esophageal varices associated with red color signs but without history of variceal bleeding were randomized to band ligation (30 patients) or treatment with nadolol plus isosorbide-5-mononitrate (ISMN) (31 patients). In the ligation group, multiband ligator with 4 elastic bands was applied during each session. Ligation was repeated at intervals of 4 weeks until variceal obliteration was achieved. In the combination group, the dose of nadolol was sufficient to reduce the pulse rate

2006 Journal of the Chinese Medical Association : JCMA Controlled trial quality: uncertain

4. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. (Abstract)

Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. beta-blockers effectively prevent first variceal bleeding (FVB) in cirrhotic patients. In patients with ascites, however, their use might be precluded by a high rate of contraindications and side effects. We compared the efficacy and applicability of nadolol and isosorbide-mononitrate (IsMn) in preventing FVB in a population of cirrhotic patients at high risk

2002 Journal of hepatology Controlled trial quality: uncertain

5. Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices [Cochrane Protocol]

Beta-blockers alone or with isosorbide mononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO

6. Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor

Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03523754 Recruitment Status : Active, not recruiting First Posted : May 14, 2018

2018 Clinical Trials

7. The Relationship between Compound Danshen Dripping Pills with Isosorbide Mononitrate in the Treatment of Elderly Patients with Unstable Angina Pectoris. Full Text available with Trip Pro

The Relationship between Compound Danshen Dripping Pills with Isosorbide Mononitrate in the Treatment of Elderly Patients with Unstable Angina Pectoris. To evaluate the clinical efficacy and safety of Compound Danshen Dripping Pill (CDDP) and Isosorbide Mononitrate (ISMN) in the treatment of unstable angina pectoris (UAP) in the elderly.CNKI, Wanfang, VIP, CBM, and PubMed databases were searched for appropriate articles without language limitations on keywords. RevMan 5.3 software was used

2018 Evidence-based Complementary and Alternative Medicine (eCAM)

8. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. (Abstract)

Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. It is clearly established that beta-blockers decrease the risk of a first variceal bleeding in cirrhosis. We have recently shown that the addition of isosorbide mononitrate to nadolol decreases the rate of variceal bleeding in patients with cirrhosis and varices, compared with nadolol alone, after a median follow-up of 30 months (...) . It is not established if the long-term treatment with the combination continues to be beneficial. Therefore, we assessed the long-term effect of this combination on first variceal bleeding, complications, and death. One hundred forty-six cirrhotic patients with esophageal varices included in a previously published multicenter, randomized study comparing nadolol (40-160 mg/d) with the combination nadolol plus isosorbide mononitrate (10-20 mg 3 times per day) were followed up for up to 7 years (median follow-up, 55

2000 Hepatology Controlled trial quality: uncertain

9. [Effects of isosorbide-5-mononitrate on exercise capacity, prostacyclin synthesis, the renin-aldosterone axis and catecholamines in patients with cardiac insufficiency]. (Abstract)

[Effects of isosorbide-5-mononitrate on exercise capacity, prostacyclin synthesis, the renin-aldosterone axis and catecholamines in patients with cardiac insufficiency]. Isosorbide-5-mononitrate (IS-5-MN) is an active metabolite of isosorbide dinitrate with a longer plasma half life. Aim of the study was the evaluation of the effects of 40 mg/day of IS-5-MN on exercise capacity in patients with heart failure NYHA class II. After 1 week of wash-out, 10 patients with heart failure NYHA Class II

1989 Cardiologia (Rome, Italy)

10. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. Full Text available with Trip Pro

Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. Lacunar stroke, a frequent clinical manifestation of small vessel disease (SVD), differs pathologically from other ischaemic stroke subtypes and has no specific long-term secondary prevention. Licenced drugs, isosorbide mononitrate (ISMN) and cilostazol, have

2019 Eclinicalmedicine Controlled trial quality: predicted high

11. When transfering a patient from isosorbide dinitrate standard release to isosorbide mononitrate standard release, is it a same dosage switch?

When transfering a patient from isosorbide dinitrate standard release to isosorbide mononitrate standard release, is it a same dosage switch? When transfering a patient from isosorbide dinitrate standard release to isosorbide mononitrate standard release, is it a same dosage switch? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title (...) aim to deliver for every single search. As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com When transfering a patient from isosorbide dinitrate standard release to isosorbide mononitrate

2007 TRIP Answers

12. Is there any benefit of a patient taking isosorbide dinitrate instead of isosorbide mononitrate in all patients and would this advise differ in patients who have had a MI?

Is there any benefit of a patient taking isosorbide dinitrate instead of isosorbide mononitrate in all patients and would this advise differ in patients who have had a MI? Is there any benefit of a patient taking isosorbide dinitrate instead of isosorbide mononitrate in all patients and would this advise differ in patients who have had a MI? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only (...) dinitrate instead of isosorbide mononitrate in all patients and would this advise differ in patients who have had a MI? Unfortunately, we could find no robust, definitive answer to your question. As such we would like to refer your question to a specialist medicines information unit. If you wish us to do this can you let us know via ‘Contact us’ ( ) Answered 19 July 2007 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2007 TRIP Answers

13. Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices [Cochrane Protocol]

Beta-blockers alone or in combination with isosorbide mononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2016 PROSPERO

14. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. Full Text available with Trip Pro

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients.In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide (...) pro-brain natriuretic peptide (NT-proBNP).In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439

2015 NEJM Controlled trial quality: predicted high

15. Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial. Full Text available with Trip Pro

Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial. Background: Cilostazol and isosorbide mononitrate (ISMN) are candidate treatments for cerebral small vessel disease and lacunar ischaemic stroke. As both drugs may influence hemoglobin and platelet count, and hemodynamics, we sought to assess their effects in the lacunar

2019 Frontiers in neurology Controlled trial quality: uncertain

16. Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate. (Abstract)

Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate. About one-third of patients undergoing percutaneous coronary interventions (PCIs) for flow-limiting coronary stenosis continue to develop signs of myocardial ischemia (MI) during exercise stress test [EST], despite successful coronary revascularization. Coronary microvascular dysfunction is a likely major cause of the persistence of EST-induced MI (...) in these patients.We studied 15 patients (14 men, age 67±5 years) fulfilling the following strict inclusion criteria: (1) recent PCI (<6 months), with drug-eluting stent, of coronary artery stenoses for stable angina, with evidence of full success (no residual stenosis >20% in any vessel); (2) persistence of ST-segment depression induction during EST. After a basal investigation, patients received either ranolazine (375 mg bid) or isosorbide-5-mononitrate (ISMN, 20 mg bid) for 3 weeks in a single-blind, randomized

2018 European review for medical and pharmacological sciences Controlled trial quality: uncertain

17. Clinical study of isosorbide mononitrate treatment for angina pectoris in coronary heart disease. Full Text available with Trip Pro

Clinical study of isosorbide mononitrate treatment for angina pectoris in coronary heart disease. The aim of this study was to observe and investigate the clinical efficacy of an intravenous drip of isosorbide mononitrate (ISMN) for the treatment of angina pectoris in coronary heart disease. A total of 102 patients with angina pectoris in coronary heart disease were divided into two groups. For the treatment group (n=51), 20 mg ISMN was added to 250 ml 0.9% normal saline and administered

2013 Experimental and therapeutic medicine Controlled trial quality: uncertain

18. A randomized clinical trial of the effects of isosorbide mononitrate on bone formation and resorption in post-menopausal women: a pilot study. Full Text available with Trip Pro

A randomized clinical trial of the effects of isosorbide mononitrate on bone formation and resorption in post-menopausal women: a pilot study. 16997941 2006 11 14 2019 02 25 0268-1161 21 10 2006 Oct Human reproduction (Oxford, England) Hum. Reprod. A randomized clinical trial of the effects of isosorbide mononitrate on bone formation and resorption in post-menopausal women: a pilot study. 2466 eng Retraction of Publication England Hum Reprod 8701199 0268-1161 Nabhan AF. Hum Reprod. 2006 May;21

2006 Human reproduction (Oxford, England) Controlled trial quality: uncertain

19. [Effects of isosorbide-5-mononitrate on esophageal manometry of cirrhotic patients with esophageal varices]. (Abstract)

[Effects of isosorbide-5-mononitrate on esophageal manometry of cirrhotic patients with esophageal varices]. 16092992 2007 08 23 2016 11 24 1007-3418 13 8 2005 Aug Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Zhonghua Gan Zang Bing Za Zhi [Effects of isosorbide-5-mononitrate on esophageal manometry of cirrhotic patients with esophageal varices]. 611-2 Lin Xiang-fei XF Department of Gastroenterology, First Affiliated Hospital of Wenzhou Medical (...) College, Wenzhou 325000, China. linxiangfei0578@sina.com Wu Jin-ming JM Lin Xiu-ying XY Chen Min-xin MX Zhu Qi-huai QH Wu Xiao-li XL chi Journal Article Randomized Controlled Trial China Zhonghua Gan Zang Bing Za Zhi 9710009 1007-3418 0 Vasodilator Agents IA7306519N Isosorbide Dinitrate LX1OH63030 isosorbide-5-mononitrate IM Adult Esophageal and Gastric Varices drug therapy etiology physiopathology Esophagus physiopathology Female Humans Isosorbide Dinitrate analogs & derivatives therapeutic use Liver

2007 Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Controlled trial quality: uncertain

20. [Mononitrates in long-term prophylaxis of angina pectoris: results of the first isosorbid-5-mononitrate symposium in Mannheim]. (Abstract)

[Mononitrates in long-term prophylaxis of angina pectoris: results of the first isosorbid-5-mononitrate symposium in Mannheim]. 7024071 1981 11 18 2013 11 21 0015-8178 99 6 1981 Feb 12 Fortschritte der Medizin Fortschr. Med. [Mononitrates in long-term prophylaxis of angina pectoris: results of the first isosorbid-5-mononitrate symposium in Mannheim]. 200-2 ger Clinical Trial Controlled Clinical Trial Journal Article Randomized Controlled Trial Mononitrat zur Langzeitprophylaxe der Angina (...) pectoris. Ergebnisse des 1. Isosorbid-5-Mononitrate-Symposium in Mannheim. Germany Fortschr Med 2984763R 0015-8178 IA7306519N Isosorbide Dinitrate IM Angina Pectoris prevention & control Clinical Trials as Topic Germany, West Humans Isosorbide Dinitrate analogs & derivatives therapeutic use 1981 2 12 1981 2 12 0 1 1981 2 12 0 0 ppublish 7024071

1981 Fortschritte Der Medizin Controlled trial quality: uncertain